We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MLD

News List

NICE recommends first treatment for children with metachromatic leukodystrophy EuropeanPharmaceuticalReview
February 09, 2022
The one-time gene therapy treatment for rare, neurodegenerative disease metachromatic leukodystrophy (MLD) is the most expensive drug ever evaluated by NICE.
NICE ‘no’ for Orchard Therapeutics’ gene therapy Libmeldy pharmatimes
July 13, 2021
The National Institute for Health and Care Excellence (NICE) has announced that it does not recommend Orchard Therapeutics’ gene therapy Libmeldy for the treatment of metachromatic leukodystrophy (MLD) in children.
Orchard Therapeutics Announces OTL-200 Granted RMAT Designation americanpharmaceuticalreview
January 21, 2021
Orchard Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OTL-200, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the ...